The next-generation version of the Open Targets Platform — the culmination of two years of work — is now officially live! It replaces our previous version, with a fresh new look, brand new features, and streamlined processes.
It is available at platform.opentargets.org
This presentation goes through the main changes to the Platform, and introduces the new Open Targets Community forum. Join now at community.opentargets.org.
Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation. Find out more at opentargets.org
2. KeyPoints
Complete refactoring of the codebase
Overhaul of the user interface
New features and data
Allowing for rapid development and deployment strategies
Improving user experience and access to information
From our latest data release — 21.04
4. Newdata&
approaches
Increase in target-disease evidence
As part of our project-wide rewrite efforts,
we have completely overhauled our evidence
data model. We have a new data schema that
is flatter and more streamlined, allowing for
much more efficient analysis of the evidence
across different data sources.
platform.opentargets.org
6. Binary molecular interactions
Our pipeline integrates different pairwise
interactions — physical, regulatory,
functional — between the selected target
and all other human or pathogenic (e.g.
SARS-CoV2) proteins and RNA molecules.
platform.opentargets.org
7. Sourcesofmolecular
interactiondata
platform.opentargets.org
Intact Reactome Signor STRING
Genes and proteins which interact typically
work together in the same processes, and
are therefore more likely to be associated in
disease. Molecular interactions can indicate
other potentially relevant targets, or
increase the confidence in a given target.
8. Black box warnings
A black box warning, or boxed warning, is the
FDA’s most severe warning for drugs on the
market, indicating serious side effects such as
injury or death.
Thanks to work from our colleagues at
ChEMBL, this information is now available in
the Open Targets Platform.
platform.opentargets.org
Hunter FMI, Bento AP, Bosc N, et al. Drug Safety Data
Curation and Modeling in ChEMBL: Boxed Warnings and
Withdrawn Drugs. Chemical Research in Toxicology. 2021
Feb;34(2):385-395.
9. Our recent work has classified the type of adverse
effect described in boxed warnings on a per drug
basis. For medicinal products that contain one active
pharmaceutical ingredient, a boxed warning can be
directly linked to a drug.
Therefore, toxicity class(es) have been assigned to
approved drugs with boxed warning information
described on medicinal product labels.
platform.opentargets.org
10. Uniprot Variants
With this latest release, we are re-
introducing the variant-based target-
disease evidence source from Uniprot. It
complements the curated associations in
the ClinVar evidence set with an additional
7127 unique variants, as well as further
curated information.
platform.opentargets.org
11. A new literature mining strategy
Through collaboration with Europe
PubMedCentral, we created a new literature-
mining strategy using natural language
processing, which is noticeably more
accurate.
Our new pipeline uses a deep learning
method for named entity recognition and
reports sentence level target-disease co-
occurrences as associations.
platform.opentargets.org
12. New algorithms to explore entities
We have implemented new algorithms to
explore the universe of entities and their
similarities in the literature.
This allows us to display significantly more
relevant publications, and enables users to
explore different entities mentioned similarly
in the literature.
platform.opentargets.org
13. platform.opentargets.org
Clinical signs
& symptoms
Clinical signs and symptoms
associated with diseases
provide more detailed
evidence connecting targets
and diseases.
Evidence pages
Compared to the previous
version, the evidence pages
have a completely new design.
Each data source has its own
section for easy navigation.
Literature
We have made our literature
sources easier to navigate, with
the full reference displayed. We
also indicate whether the full
text is available
Additional features
14. Redesigned
infrastructure
The technical stack for the next-generation
Open Targets Platform has been completely
overhauled. This has enabled us to
implement an entirely new ETL pipeline, API
and web application, using powerful modern
technologies.
platform.opentargets.org
15. platform.opentargets.org
The user interface has been both redesigned
and completely reimplemented in order to
maximise the impact of casual findings. The
underlying algorithms provide flexible, on-the-
fly calculations of association scores, and as
such, unblock more user-driven queries.
This also enables much faster development
and deployment strategies, facilitating the
implementation of custom instances of the
Platform.
16. Dataaccess
options
Depending on the complexity of the query
and the user’s programmatic skills, we have
a range of ways to access our data.
platform.opentargets.org
17. platform.opentargets.org
Users can use the search function on our
web interface, and navigate to entity pages,
associations pages, or evidence pages. Data
tables and visualisations can be downloaded
in multiple formats.
Web application
The GraphQL API provides a friendly,
language-agnostic access point to the
information displayed in the web application.
The GraphQL playground contains a schema
to help you construct tailored queries.
GraphQL API
Single entities
or associations
18. platform.opentargets.org
Google BigQuery allows you to run
asynchronous SQL queries using Google
Cloud’s infrastructure, and export the results
or copy them into Google Cloud buckets.
Google BigQuery
We also provide downloads for all data files
generated by our ETL pipelines, with more
than 20 datasets available. These data
downloads contain information on all targets,
diseases/phenotypes, and drugs, allowing
users to explore specific datasets and
integrate them into their own pipelines.
Data downloads
Complex
queries